{"id":762325,"date":"2023-06-08T00:23:46","date_gmt":"2023-06-08T04:23:46","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/burning-rocks-precision-oncology-diagnostics-product-supports-advancement-in-late-stage-breast-cancer-treatment-with-results-published-in-the-new-england-journal-of-medicine\/"},"modified":"2023-06-08T00:23:46","modified_gmt":"2023-06-08T04:23:46","slug":"burning-rocks-precision-oncology-diagnostics-product-supports-advancement-in-late-stage-breast-cancer-treatment-with-results-published-in-the-new-england-journal-of-medicine","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/burning-rocks-precision-oncology-diagnostics-product-supports-advancement-in-late-stage-breast-cancer-treatment-with-results-published-in-the-new-england-journal-of-medicine\/","title":{"rendered":"Burning Rock&#8217;s precision oncology diagnostics product supports advancement in late-stage breast cancer treatment, with results published in the New England Journal of Medicine"},"content":{"rendered":"<div class=\"mw_release\">\n<p>GUANGZHOU, China, June  08, 2023  (GLOBE NEWSWIRE) &#8212; Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the \u201cCompany\u201d or \u201cBurning Rock\u201d) is pleased to announce that our flagship comprehensive genomic profiling (CGP) product, OncoScreen<sup>TM<\/sup> Plus, was featured in a phase 3 multi-regional clinical trial (MRCT), along with FoundationOneCDx, in support of advancement in breast cancer treatment.<\/p>\n<p>The study, CAPItello-291, sponsored by our pharma client AstraZeneca, is a phase 3 trial that assessed the efficacy and safety of Capivasertib\u2013fulvestrant therapy in advanced breast cancer patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) cancer whose disease had progressed during or after aromatase inhibitor therapy. The study demonstrated that Capivasertib\u2013fulvestrant combination therapy resulted in significantly longer progression-free survival than treatment with fulvestrant alone.<\/p>\n<p>In the study, Burning Rock&#8217;s flagship comprehensive genomic profiling (CGP) product, OncoScreen<sup>TM<\/sup> Plus, was used to determine activating mutations in PIK3CA and AKT1 and inactivating alterations in PTEN genes for patients enrolled in China. We are proud to have supported our pharma client in such a high impact study, after a rigorous test solution provider evaluation process.<\/p>\n<p>\n        <strong>Reference<\/strong><br \/>\n        <br \/>[1] Capivasertib in Hormone Receptor\u2013Positive Advanced Breast Cancer. N ENGL J MED 388. June, 2023<br \/>https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2214131<\/p>\n<p>\n        <strong>About Burning Rock<\/strong><br \/>\n        <br \/>Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR), whose mission is to guard life via science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, and ii) cancer early detection, which has moved beyond proof-of-concept R&amp;D into the clinical validation stage.<\/p>\n<p>For more information about Burning Rock, please visit: www.brbiotech.com.<\/p>\n<p>Enquiries:<br \/>Contact: IR@brbiotech.com<\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1NDYzNSM1NjM3NDM5IzIxOTUyNTk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NDc4YTYxNjYtZWI5NS00N2M1LTgyNTItZWQ4ZDEyNmZiMmNjLTEyMDY4MTI=\/tiny\/Burning-Rock-Biotech-Limited.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>GUANGZHOU, China, June 08, 2023 (GLOBE NEWSWIRE) &#8212; Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the \u201cCompany\u201d or \u201cBurning Rock\u201d) is pleased to announce that our flagship comprehensive genomic profiling (CGP) product, OncoScreenTM Plus, was featured in a phase 3 multi-regional clinical trial (MRCT), along with FoundationOneCDx, in support of advancement in breast cancer treatment. The study, CAPItello-291, sponsored by our pharma client AstraZeneca, is a phase 3 trial that assessed the efficacy and safety of Capivasertib\u2013fulvestrant therapy in advanced breast cancer patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) cancer whose disease had progressed during or after aromatase inhibitor therapy. The study demonstrated that Capivasertib\u2013fulvestrant combination therapy resulted in significantly longer &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/burning-rocks-precision-oncology-diagnostics-product-supports-advancement-in-late-stage-breast-cancer-treatment-with-results-published-in-the-new-england-journal-of-medicine\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Burning Rock&#8217;s precision oncology diagnostics product supports advancement in late-stage breast cancer treatment, with results published in the New England Journal of Medicine&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-762325","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Burning Rock&#039;s precision oncology diagnostics product supports advancement in late-stage breast cancer treatment, with results published in the New England Journal of Medicine - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/burning-rocks-precision-oncology-diagnostics-product-supports-advancement-in-late-stage-breast-cancer-treatment-with-results-published-in-the-new-england-journal-of-medicine\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Burning Rock&#039;s precision oncology diagnostics product supports advancement in late-stage breast cancer treatment, with results published in the New England Journal of Medicine - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"GUANGZHOU, China, June 08, 2023 (GLOBE NEWSWIRE) &#8212; Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the \u201cCompany\u201d or \u201cBurning Rock\u201d) is pleased to announce that our flagship comprehensive genomic profiling (CGP) product, OncoScreenTM Plus, was featured in a phase 3 multi-regional clinical trial (MRCT), along with FoundationOneCDx, in support of advancement in breast cancer treatment. The study, CAPItello-291, sponsored by our pharma client AstraZeneca, is a phase 3 trial that assessed the efficacy and safety of Capivasertib\u2013fulvestrant therapy in advanced breast cancer patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) cancer whose disease had progressed during or after aromatase inhibitor therapy. The study demonstrated that Capivasertib\u2013fulvestrant combination therapy resulted in significantly longer &hellip; Continue reading &quot;Burning Rock&#8217;s precision oncology diagnostics product supports advancement in late-stage breast cancer treatment, with results published in the New England Journal of Medicine&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/burning-rocks-precision-oncology-diagnostics-product-supports-advancement-in-late-stage-breast-cancer-treatment-with-results-published-in-the-new-england-journal-of-medicine\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-08T04:23:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1NDYzNSM1NjM3NDM5IzIxOTUyNTk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/burning-rocks-precision-oncology-diagnostics-product-supports-advancement-in-late-stage-breast-cancer-treatment-with-results-published-in-the-new-england-journal-of-medicine\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/burning-rocks-precision-oncology-diagnostics-product-supports-advancement-in-late-stage-breast-cancer-treatment-with-results-published-in-the-new-england-journal-of-medicine\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Burning Rock&#8217;s precision oncology diagnostics product supports advancement in late-stage breast cancer treatment, with results published in the New England Journal of Medicine\",\"datePublished\":\"2023-06-08T04:23:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/burning-rocks-precision-oncology-diagnostics-product-supports-advancement-in-late-stage-breast-cancer-treatment-with-results-published-in-the-new-england-journal-of-medicine\\\/\"},\"wordCount\":310,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/burning-rocks-precision-oncology-diagnostics-product-supports-advancement-in-late-stage-breast-cancer-treatment-with-results-published-in-the-new-england-journal-of-medicine\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg1NDYzNSM1NjM3NDM5IzIxOTUyNTk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/burning-rocks-precision-oncology-diagnostics-product-supports-advancement-in-late-stage-breast-cancer-treatment-with-results-published-in-the-new-england-journal-of-medicine\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/burning-rocks-precision-oncology-diagnostics-product-supports-advancement-in-late-stage-breast-cancer-treatment-with-results-published-in-the-new-england-journal-of-medicine\\\/\",\"name\":\"Burning Rock's precision oncology diagnostics product supports advancement in late-stage breast cancer treatment, with results published in the New England Journal of Medicine - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/burning-rocks-precision-oncology-diagnostics-product-supports-advancement-in-late-stage-breast-cancer-treatment-with-results-published-in-the-new-england-journal-of-medicine\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/burning-rocks-precision-oncology-diagnostics-product-supports-advancement-in-late-stage-breast-cancer-treatment-with-results-published-in-the-new-england-journal-of-medicine\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg1NDYzNSM1NjM3NDM5IzIxOTUyNTk=\",\"datePublished\":\"2023-06-08T04:23:46+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/burning-rocks-precision-oncology-diagnostics-product-supports-advancement-in-late-stage-breast-cancer-treatment-with-results-published-in-the-new-england-journal-of-medicine\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/burning-rocks-precision-oncology-diagnostics-product-supports-advancement-in-late-stage-breast-cancer-treatment-with-results-published-in-the-new-england-journal-of-medicine\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/burning-rocks-precision-oncology-diagnostics-product-supports-advancement-in-late-stage-breast-cancer-treatment-with-results-published-in-the-new-england-journal-of-medicine\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg1NDYzNSM1NjM3NDM5IzIxOTUyNTk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg1NDYzNSM1NjM3NDM5IzIxOTUyNTk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/burning-rocks-precision-oncology-diagnostics-product-supports-advancement-in-late-stage-breast-cancer-treatment-with-results-published-in-the-new-england-journal-of-medicine\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Burning Rock&#8217;s precision oncology diagnostics product supports advancement in late-stage breast cancer treatment, with results published in the New England Journal of Medicine\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Burning Rock's precision oncology diagnostics product supports advancement in late-stage breast cancer treatment, with results published in the New England Journal of Medicine - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/burning-rocks-precision-oncology-diagnostics-product-supports-advancement-in-late-stage-breast-cancer-treatment-with-results-published-in-the-new-england-journal-of-medicine\/","og_locale":"en_US","og_type":"article","og_title":"Burning Rock's precision oncology diagnostics product supports advancement in late-stage breast cancer treatment, with results published in the New England Journal of Medicine - Market Newsdesk","og_description":"GUANGZHOU, China, June 08, 2023 (GLOBE NEWSWIRE) &#8212; Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the \u201cCompany\u201d or \u201cBurning Rock\u201d) is pleased to announce that our flagship comprehensive genomic profiling (CGP) product, OncoScreenTM Plus, was featured in a phase 3 multi-regional clinical trial (MRCT), along with FoundationOneCDx, in support of advancement in breast cancer treatment. The study, CAPItello-291, sponsored by our pharma client AstraZeneca, is a phase 3 trial that assessed the efficacy and safety of Capivasertib\u2013fulvestrant therapy in advanced breast cancer patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) cancer whose disease had progressed during or after aromatase inhibitor therapy. The study demonstrated that Capivasertib\u2013fulvestrant combination therapy resulted in significantly longer &hellip; Continue reading \"Burning Rock&#8217;s precision oncology diagnostics product supports advancement in late-stage breast cancer treatment, with results published in the New England Journal of Medicine\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/burning-rocks-precision-oncology-diagnostics-product-supports-advancement-in-late-stage-breast-cancer-treatment-with-results-published-in-the-new-england-journal-of-medicine\/","og_site_name":"Market Newsdesk","article_published_time":"2023-06-08T04:23:46+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1NDYzNSM1NjM3NDM5IzIxOTUyNTk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/burning-rocks-precision-oncology-diagnostics-product-supports-advancement-in-late-stage-breast-cancer-treatment-with-results-published-in-the-new-england-journal-of-medicine\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/burning-rocks-precision-oncology-diagnostics-product-supports-advancement-in-late-stage-breast-cancer-treatment-with-results-published-in-the-new-england-journal-of-medicine\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Burning Rock&#8217;s precision oncology diagnostics product supports advancement in late-stage breast cancer treatment, with results published in the New England Journal of Medicine","datePublished":"2023-06-08T04:23:46+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/burning-rocks-precision-oncology-diagnostics-product-supports-advancement-in-late-stage-breast-cancer-treatment-with-results-published-in-the-new-england-journal-of-medicine\/"},"wordCount":310,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/burning-rocks-precision-oncology-diagnostics-product-supports-advancement-in-late-stage-breast-cancer-treatment-with-results-published-in-the-new-england-journal-of-medicine\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1NDYzNSM1NjM3NDM5IzIxOTUyNTk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/burning-rocks-precision-oncology-diagnostics-product-supports-advancement-in-late-stage-breast-cancer-treatment-with-results-published-in-the-new-england-journal-of-medicine\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/burning-rocks-precision-oncology-diagnostics-product-supports-advancement-in-late-stage-breast-cancer-treatment-with-results-published-in-the-new-england-journal-of-medicine\/","name":"Burning Rock's precision oncology diagnostics product supports advancement in late-stage breast cancer treatment, with results published in the New England Journal of Medicine - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/burning-rocks-precision-oncology-diagnostics-product-supports-advancement-in-late-stage-breast-cancer-treatment-with-results-published-in-the-new-england-journal-of-medicine\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/burning-rocks-precision-oncology-diagnostics-product-supports-advancement-in-late-stage-breast-cancer-treatment-with-results-published-in-the-new-england-journal-of-medicine\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1NDYzNSM1NjM3NDM5IzIxOTUyNTk=","datePublished":"2023-06-08T04:23:46+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/burning-rocks-precision-oncology-diagnostics-product-supports-advancement-in-late-stage-breast-cancer-treatment-with-results-published-in-the-new-england-journal-of-medicine\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/burning-rocks-precision-oncology-diagnostics-product-supports-advancement-in-late-stage-breast-cancer-treatment-with-results-published-in-the-new-england-journal-of-medicine\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/burning-rocks-precision-oncology-diagnostics-product-supports-advancement-in-late-stage-breast-cancer-treatment-with-results-published-in-the-new-england-journal-of-medicine\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1NDYzNSM1NjM3NDM5IzIxOTUyNTk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1NDYzNSM1NjM3NDM5IzIxOTUyNTk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/burning-rocks-precision-oncology-diagnostics-product-supports-advancement-in-late-stage-breast-cancer-treatment-with-results-published-in-the-new-england-journal-of-medicine\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Burning Rock&#8217;s precision oncology diagnostics product supports advancement in late-stage breast cancer treatment, with results published in the New England Journal of Medicine"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/762325","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=762325"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/762325\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=762325"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=762325"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=762325"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}